Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.

The therapeutic effect of iron (Fe) chelators on the potentially toxic plasma pool of nontransferrin-bound iron (NTBI), often present in Fe overload diseases and in some cancer patients during chemotherapy, is of considerable interest. In the present investigation, several multidentate pyridinones were synthesized and compared with their bidentate analogue, deferiprone (DFP; L1, orally active) and desferrioxamine (DFO; hexadentate; orally inactive) for their effect on the metabolism of NTBI in the rat hepatocyte and a hepatoma cell line (McArdle 7777, Q7). Hepatoma cells took up much less NTBI than the hepatocytes (< 10%). All the chelators inhibited NTBI uptake (80-98%) much more than they increased mobilization of Fe from cells prelabelled with NTBI (5-20%). The hexadentate pyridinone, N,N,N-tris(3-hydroxy-1-methyl-2(1H)-pyridinone-4-carboxaminoethyl)amine showed comparable activity to DFO and DFP. There was no apparent correlation between Fe status, Fe uptake and chelator activity in hepatocytes, suggesting that NTBI transport is not regulated by cellular Fe levels. The intracellular distribution of iron taken up as NTBI changed in the presence of chelators suggesting that the chelators may act intracellularly as well as at the cell membrane. In conclusion (a) rat hepatocytes have a much greater capacity to take up NTBI than the rat hepatoma cell line (Q7), (b) all chelators bind NTBI much more effectively during the uptake phase than in the mobilization of Fe which has been stored from NTBI and (c) while DFP is the most active chelator, other multidentate pyridinones have potential in the treatment of Fe overload, particularly at lower, more readily clinically available concentrations, and during cancer chemotherapy, by removing plasma NTBI.

[1]  Dr. R. G. Batey Fracp,et al.  A non-transferrin-bound serum iron in idiopathic hemochromatosis , 2005, Digestive Diseases and Sciences.

[2]  J. Papadimitriou,et al.  Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig , 1997, Biometals.

[3]  A. Konijn,et al.  Acquisition, storage and release of iron by cultured human hepatoma cells. , 2002, Journal of hepatology.

[4]  D. Richardson.  The controversial role of deferiprone in the treatment of thalassemia. , 2001, The Journal of laboratory and clinical medicine.

[5]  W. Breuer,et al.  The importance of non-transferrin bound iron in disorders of iron metabolism. , 2000, Transfusion science.

[6]  M. Rayens,et al.  The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue. , 2000, Journal of pharmaceutical sciences.

[7]  H. Pati,et al.  Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience , 1999, European journal of haematology.

[8]  N. Çetingül,et al.  Sequential Use of Deferiprone and Desferrioxamine in Primary School Children with Thalassaemia major in Turkey , 1999, Acta Haematologica.

[9]  A. Taher,et al.  Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine , 1999, Acta Haematologica.

[10]  G. Koren,et al.  An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. , 1999, Therapeutic drug monitoring.

[11]  Wright,et al.  Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.

[12]  E. Morgan,et al.  Characterisation of citrate and iron citrate uptake by cultured rat hepatocytes. , 1998, Journal of hepatology.

[13]  G. Lescoat,et al.  Antiproliferative effect of deferiprone on the Hep G2 cell line. , 1998, Biochemical pharmacology.

[14]  K. Fleming,et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.

[15]  R. Hebbel,et al.  The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. , 1998, Blood.

[16]  E. Morgan,et al.  Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture. , 1998, Biochimica et biophysica acta.

[17]  S. Srichairatanakool,et al.  Non‐transferrin‐bound iron induced by myeloablative chemotherapy , 1997, British journal of haematology.

[18]  E. Morgan,et al.  Inhibition of uptake of transferrin‐bound iron by human hepatoma cells by nontransferrin‐bound iron , 1997, Hepatology.

[19]  D. Templeton,et al.  Characterization of Fe2+ and Fe3+ transport by iron-loaded cardiac myocytes. , 1997, Toxicology.

[20]  R. Hider,et al.  The Design of Orally Active Iron Chelators , 2005, Acta haematologica.

[21]  D. Richardson,et al.  Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. , 1995, Biochimica et biophysica acta.

[22]  A. Hoffbrand,et al.  Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators , 1995, British journal of haematology.

[23]  B. Halliwell,et al.  Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. , 1995, Cancer letters.

[24]  D. Templeton,et al.  Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. , 1995, Biochimica et biophysica acta.

[25]  C. Hershko,et al.  Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. , 1994, Bailliere's clinical haematology.

[26]  D. Templeton,et al.  Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. , 1994, The Journal of biological chemistry.

[27]  D. Richardson,et al.  The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. , 1994, Cancer research.

[28]  D. Templeton,et al.  Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. , 1993, The Journal of laboratory and clinical medicine.

[29]  R. Puniyani,et al.  Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.

[30]  D. Richardson,et al.  Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. , 1992, The Journal of biological chemistry.

[31]  D. Richardson,et al.  Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2‐hydroxy‐1‐naphthylaldehyde using the hepatocyte in culture , 1992, Hepatology.

[32]  A. Hoffbrand,et al.  L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia major , 1990, British journal of haematology.

[33]  J. Shainoff,et al.  Electron microscopy of platelet interactions with heme-octapeptide-labeled fibrinogen. , 1990, The American journal of physiology.

[34]  E. Morgan,et al.  Effect of cellular iron concentration on iron uptake by hepatocytes. , 1990, The American journal of physiology.

[35]  P. Sadler,et al.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.

[36]  M. Awai,et al.  PROCESS OF CARBONYL IRON ABSORPTION FROM THE RAT DUODENAL MUCOSA , 1988, Acta pathologica japonica.

[37]  E. Morgan,et al.  Characteristics of iron exchange between transferrin and hepatocytes in culture. , 1988, Birth defects original article series.

[38]  E. Morgan,et al.  Iron uptake and metabolism by hepatocytes. , 1986, Federation proceedings.

[39]  B. Halliwell,et al.  Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. , 1985, Clinical science.

[40]  E. Morgan,et al.  Transferrin and iron release from rat hepatocytes in culture. , 1985, The American journal of physiology.

[41]  B. Bacon,et al.  Hepatic lipid peroxidation in vivo in rats with chronic iron overload. , 1983, The Journal of clinical investigation.

[42]  M. Pippard,et al.  Hepatocyte iron kinetics in the rat explored with an iron chelator , 1982, British journal of haematology.

[43]  E. Rachmilewitz,et al.  Nonspecific serum iron in thalassemia: Quantitation and chemical reactivity , 1979, American journal of hematology.

[44]  G. Yeoh,et al.  Hepatocyte differentiation in culture. Appearance of tyrosine aminotransferase. , 1979, The Biochemical journal.

[45]  E. Rachmilewitz,et al.  Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.

[46]  R. Crichton,et al.  Isolation and characterization of iron-binding proteins from rat intestinal mucosa. , 1976, European journal of biochemistry.

[47]  R. Hinegardner,et al.  An improved fluorometric assay for DNA. , 1971, Analytical biochemistry.

[48]  B. Sarkar.  State of iron(3) in normal human serum: low molecular weight and protein ligands besides transferrin. , 1970, Canadian journal of biochemistry.